THE EFFECT OF RENAL-FAILURE ON HEPATIC DRUG CLEARANCE

被引:91
作者
TOUCHETTE, MA [1 ]
SLAUGHTER, RL [1 ]
机构
[1] WAYNE STATE UNIV,COLL PHARM,DEPT PHARM PRACTICE,328 SHAPERO HALL,DETROIT,MI 48202
来源
DICP-THE ANNALS OF PHARMACOTHERAPY | 1991年 / 25卷 / 11期
关键词
D O I
10.1177/106002809102501111
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It is known that loss of renal function decreases the hepatic clearance of some drugs, but the mechanisms by which this occurs are unclear. Knowledge of which drugs display reduced hepatic metabolism may be important for appropriate dosing of these drugs in uremic patients. Although no firm conclusions can be made regarding common pharmacokinetic and metabolic characteristics of drugs that display decreased hepatic metabolism in renal failure, certain observations deserve consideration. It appears that drugs metabolized by oxidation, conjugation, or both may be predisposed to decreased hepatic clearance in renal failure. Drugs that undergo oxidation by the P-450IID6 isozyme may be more likely to exhibit inhibition whereas those metabolized by the P-450IIIA4 isozyme may be spared. Future studies designed to clarify the mechanisms of decreased hepatic clearance in renal failure should take into account the multiplicity of P-450 enzymes for drugs that are oxidatively metabolized. The phenomenon of reduced hepatic drug clearance in uremia should be considered when evaluating the influence of renal failure on drug disposition.
引用
收藏
页码:1214 / 1224
页数:11
相关论文
共 76 条
  • [1] AHR G, 1987, NISOLDIPINE 1987, P59
  • [2] URINARY-EXCRETION OF NORTRIPTYLINE AND 5 OF ITS METABOLITES IN MAN AFTER SINGLE AND MULTIPLE ORAL DOSES
    ALEXANDERSON, B
    BORGA, O
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1973, 5 (03) : 174 - 180
  • [3] AVAILABILITY OF ORALLY ADMINISTERED NORTRIPTYLINE
    ALEXANDERSON, B
    BORGA, O
    ALVAN, G
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1973, 5 (03) : 181 - 185
  • [4] METABOLISM OF DRUGS BY THE KIDNEY
    ANDERS, MW
    [J]. KIDNEY INTERNATIONAL, 1980, 18 (05) : 636 - 647
  • [5] ELIMINATION AND HEMODYNAMIC-EFFECTS OF NITRENDIPINE IN PATIENTS WITH CHRONIC RENAL-FAILURE
    ANKERMANN, T
    OSTERKAMP, U
    SANTOS, SR
    KIRCH, W
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (05) : 433 - 437
  • [6] ARANOFF GR, 1984, J CARDIOVASCULAR P S, V6, pS974
  • [7] INFLUENCE OF RENAL-FAILURE ON THE HEPATIC-CLEARANCE OF BUFURALOL IN MAN
    BALANT, L
    FRANCIS, RJ
    TOZER, TN
    MARMY, A
    TSCHOPP, JM
    FABRE, J
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1980, 8 (05): : 421 - 438
  • [8] THE PHARMACOKINETICS OF SINGLE DOSES OF METOCLOPRAMIDE IN RENAL-FAILURE
    BATEMAN, DN
    GOKAL, R
    DODD, TRP
    BLAIN, PG
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 19 (06) : 437 - 441
  • [9] BAUER LA, 1982, J CLIN PHARMACOL, V22, P65, DOI 10.1002/j.1552-4604.1982.tb05710.x
  • [10] ENCAINIDE DISPOSITION IN PATIENTS WITH RENAL-FAILURE
    BERGSTRAND, RH
    WANG, T
    RODEN, DM
    STONE, WJ
    WOLFENDEN, HT
    WOOSLEY, RL
    WILKINSON, GR
    WOOD, AJJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (01) : 64 - 70